公开(公告)号：US20220089609A1

公开(公告)日：2022-03-24

申请号：US17263071

申请日：2019-07-26

申请人： DOMAIN THERAPEUTICS

发明人： Camille AMALRIC ,  Anaïs BARRE ,  Stephan SCHANN ,  Stanislas MAYER ,  Ismet DORANGE ,  Baptiste MANTEAU ,  Anne-Laure BLAYO

IPC分类号： C07D498/10 ,  C07D487/04 ,  C07D401/14 ,  C07D495/04 ,  C07D413/14 ,  C07D405/14 ,  C07D519/00 ,  A61P25/16

摘要： The present invention relates to novel quinazolinone derivatives of formula (I) as well as pharmaceutical compositions containing these compounds. The compounds of formula (I) as provided herein can act as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4), and can thus be used as therapeutic agents, particularly in the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions or conditions which can be affected by alteration of glutamate level or signalling.

公开(公告)号：US20170305913A1

公开(公告)日：2017-10-26

申请号：US15514431

申请日：2015-09-25

申请人： DOMAIN THERAPEUTICS

发明人： Stephan SCHANN ,  Stanislas MAYER ,  Baptiste MANTEAU

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

公开(公告)号：US20220378772A1

公开(公告)日：2022-12-01

申请号：US17766161

申请日：2020-10-02

申请人： Domain Therapeutics

发明人： Anne-Laure BLAYO ,  Ismet DORANGE ,  Gaël HOMMET ,  Baptiste MANTEAU ,  Stanislas MAYER ,  Stephan SCHANN

IPC分类号： A61K31/453 ,  C07D309/14 ,  C07D405/12 ,  C07C233/63 ,  C07D335/02 ,  C07D311/94 ,  C07D307/24 ,  C07D211/66 ,  C07D309/10 ,  C07D309/08 ,  C07D407/12 ,  C07D405/04 ,  C07D213/64 ,  C07D213/68 ,  C07D213/65 ,  C07D207/12 ,  C07D405/14 ,  C07D413/12 ,  C07D207/09 ,  A61P35/00 ,  A61K39/395 ,  A61K31/351 ,  A61K31/4433 ,  A61K31/196 ,  A61K31/382 ,  A61K31/352 ,  A61K31/341 ,  A61K31/4468 ,  A61K31/4418 ,  A61K31/4025 ,  A61K31/40 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/4245

摘要： The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

公开(公告)号：US20190152979A1

公开(公告)日：2019-05-23

申请号：US16251646

申请日：2019-01-18

申请人： DOMAIN THERAPEUTICS

发明人： Stephan SCHANN ,  Stanislas MAYER ,  Baptiste MANTEAU

IPC分类号： C07D487/04

摘要： Pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them are disclosed. The compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signaling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signaling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.